Quick Answer
Xilio Therapeutics, Inc. reported Cash and Equivalents of $137.53 million for fiscal year 2025.
Xilio Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $137.53M | +148.7% |
| 2024 | $55.29M | +23.7% |
| 2023 | $44.70M | -62.9% |
| 2022 | $120.39M | -39.2% |
| 2021 | $198.05M | +929.5% |
| 2020 | $19.24M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $103.76M | +69.4% | -14.6% |
| June 30, 2025 | $121.55M | +62.2% | +36.5% |
| March 31, 2025 | $89.07M | +162.1% | +61.1% |
| December 31, 2024 | $55.29M | +23.7% | -9.7% |
| September 30, 2024 | $61.26M | +2.5% | -18.3% |
| June 30, 2024 | $74.95M | -0.6% | +120.6% |
| March 31, 2024 | $33.98M | -63.6% | -24.0% |
| December 31, 2023 | $44.70M | -62.9% | -25.2% |
- Xilio Therapeutics, Inc. showed an increase of +148.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Xilio Therapeutics, Inc.’s cash and equivalents has grown by 614.9% (from $19.24 million to $137.53 million).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: